Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14365/3723
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kaplan Y.C. | - |
dc.contributor.author | Demir O. | - |
dc.date.accessioned | 2023-06-16T15:03:05Z | - |
dc.date.available | 2023-06-16T15:03:05Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1570-159X | - |
dc.identifier.uri | https://doi.org/10.2174/1570159X19666210211150856 | - |
dc.identifier.uri | https://hdl.handle.net/20.500.14365/3723 | - |
dc.description.abstract | It is challenging to balance the fetal risks associated with the use of antiepileptic drugs (AEDs) against maternal and fetal risks of seizure worsening, and therefore it is very important to define and distinguish the possible risks entailed by different AEDs. This paper aims to undertake a comprehensive review regarding the possible risks of four classical (phenytoin’ carbamazepine’ phenobarbital’ and valproate) and two newer (lamotrigine and levetiracetam) AEDs during pregnancy. The review focuses on major and organ-specific malformations’ dose-dependent risks’ mono vs polytherapy’ and clinical pharmacokinetics. A discussion regarding the safety of AED use during breastfeeding is also provided. © 2021 Bentham Science Publishers | en_US |
dc.language.iso | en | en_US |
dc.publisher | Bentham Science Publishers | en_US |
dc.relation.ispartof | Current Neuropharmacology | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Antiepileptics | en_US |
dc.subject | Breastfeeding | en_US |
dc.subject | Carbamazepine | en_US |
dc.subject | Lamotrigine | en_US |
dc.subject | Levetiracetam | en_US |
dc.subject | Major malformations | en_US |
dc.subject | Phenobarbital | en_US |
dc.subject | Phenytoin | en_US |
dc.subject | Pregnancy | en_US |
dc.subject | Valproate | en_US |
dc.subject | carbamazepine | en_US |
dc.subject | cytochrome P450 2B6 | en_US |
dc.subject | cytochrome P450 2C9 | en_US |
dc.subject | lamotrigine | en_US |
dc.subject | levetiracetam | en_US |
dc.subject | phenobarbital | en_US |
dc.subject | phenytoin | en_US |
dc.subject | valproic acid | en_US |
dc.subject | anticonvulsive agent | en_US |
dc.subject | carbamazepine | en_US |
dc.subject | lamotrigine | en_US |
dc.subject | levetiracetam | en_US |
dc.subject | phenobarbital | en_US |
dc.subject | phenytoin | en_US |
dc.subject | valproic acid | en_US |
dc.subject | body weight loss | en_US |
dc.subject | breast feeding | en_US |
dc.subject | cardiovascular malformation | en_US |
dc.subject | cholestatic hepatitis | en_US |
dc.subject | cleft lip | en_US |
dc.subject | congenital malformation | en_US |
dc.subject | drug safety | en_US |
dc.subject | female | en_US |
dc.subject | gestational age | en_US |
dc.subject | human | en_US |
dc.subject | hypospadias | en_US |
dc.subject | leg inequality | en_US |
dc.subject | liver injury | en_US |
dc.subject | monotherapy | en_US |
dc.subject | muscle hypotonia | en_US |
dc.subject | neural tube | en_US |
dc.subject | pregnancy | en_US |
dc.subject | prevalence | en_US |
dc.subject | Review | en_US |
dc.subject | seizure | en_US |
dc.subject | spinal dysraphism | en_US |
dc.subject | breast feeding | en_US |
dc.subject | epilepsy | en_US |
dc.subject | pregnancy | en_US |
dc.subject | pregnancy complication | en_US |
dc.subject | Anticonvulsants | en_US |
dc.subject | Breast Feeding | en_US |
dc.subject | Carbamazepine | en_US |
dc.subject | Epilepsy | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Lamotrigine | en_US |
dc.subject | Levetiracetam | en_US |
dc.subject | Phenobarbital | en_US |
dc.subject | Phenytoin | en_US |
dc.subject | Pregnancy | en_US |
dc.subject | Pregnancy Complications | en_US |
dc.subject | Valproic Acid | en_US |
dc.title | Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamot-E rigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications | en_US |
dc.type | Review | en_US |
dc.identifier.doi | 10.2174/1570159X19666210211150856 | - |
dc.identifier.pmid | 33573557 | en_US |
dc.identifier.scopus | 2-s2.0-85119579157 | en_US |
dc.authorscopusid | 56541140000 | - |
dc.identifier.volume | 19 | en_US |
dc.identifier.issue | 11 | en_US |
dc.identifier.startpage | 1805 | en_US |
dc.identifier.endpage | 1824 | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.identifier.scopusquality | Q1 | - |
dc.identifier.wosquality | Q1 | - |
item.openairetype | Review | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
18
checked on Nov 20, 2024
Page view(s)
92
checked on Nov 25, 2024
Download(s)
22
checked on Nov 25, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.